ROCK1 and metabolic dysfunction-associated steatohepatitis: Treatment with ROCK inhibitors and genetic ablation of ROCK1 have also been shown to ameliorate inflammation and fibrosis in rodent models of NASH, as well as hepatic steatosis and insulin resistance (79, 80).